Reports
Reports
The global small molecule targeted cancer therapy market is expected to witness moderate growth during the forecast period between 2021 and 2031.
Small molecule targeted cancer therapy market refers to a drug that prevents the development of cancer cells by eliminating the targeted molecules, which leads to tumor growth.
Small molecule targeted cancer therapy has become a preferred choice over traditional treatment methods as it has helped eliminate harmful radiation from normal cells.
Targeted cancer therapy deploys drugs that particularly target cancer-specific genes, proteins, which help in cancer cells growth and development.
The small sizes of these molecules help them to move comfortably through the plasma membrane and they can integrate easily with the other molecules and cell-surface receptors domain.
Small molecule targeted cancer therapy has been deployed to cure several diseases such as lymphoma, melanoma, multiple myeloma, breast cancer, and prostate cancer.
Rising procedure adoption owing to factors such as reduced side effects is the key growth driver for the global small molecule targeted cancer therapy market.
Also, increasing incidences of chronic diseases such as cancer is anticipated to fuel the demand for small molecule targeted cancer therapy, in the upcoming years.
Government initiatives and measures, promoting the benefits of small molecule targeted cancer therapy is anticipated to fuel the demand for the recovery procedure in the years ahead.
The hospital end-use segment is expected to make the largest contribution to the overall market due to the increased adoption of small molecule targeted cancer therapy in healthcare infrastructure facilities in countries such as US and Canada.
The breast cancer application segment is expected to contribute the most to the overall small molecule targeted cancer therapy market due to the increasing incidence of the disease in several leading economies, worldwide.
The global small molecule targeted cancer therapy market is extremely competitive, with the presence of several well-established players, many of whom are expected to account for a large share in the overall market, in the years ahead.
Prominent players are expected to make huge investments in research and development activities in a bid to produce an improved quality of products, which would meet the customer requirements and increase the consumer base.
The smaller players in the global market will seek investments from governments and private investors, which could help them in their long-term growth.
Some of the prominent players in the global market include Bayer Healthcare AG, Abbott Laboratories, Cytokinetics Inc., and GlaxoSmithKline LLC.
The global small molecule targeted cancer therapy market is classified into four regions, namely, North America, Europe, Asia Pacific, and rest of the world.
North America is expected to be the dominant region in the small molecule targeted cancer therapy market owing to the rising incidence of diseases such as cancer in countries such as US and Canada.
Europe is expected to witness substantial growth in the small molecule targeted cancer therapy market due to extensive research and development undertakings conducted by countries such as UK and Germany, contributing largely to the growth of the market in the region.
The market in the region could witness further increased pace of growth if leading players decide to establish R&D centers in the countries, belonging to the region.
Asia Pacific is expected to witness moderate growth in the overall market because of developing healthcare infrastructure facilities such as India and Indonesia.
The rest of the world is expected to witness sluggish growth in the small molecule targeted cancer therapy market, in the upcoming years.
N/A
N/A
N/A
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Small Molecule Targeted Cancer Therapy Market
